Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 8/20 | 0.62 |
| ▸ | TOP2B | Q02880 | 7/20 | 0.62 |
| ▸ | KDM1A | O60341 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | RAD52 | P43351 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | TYMS | P04818 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3990019 | 0.93 | TOP2A (0.60) | TOP2ATOP2BKDM1APOLBRAD52 | |
| SCHEMBL7564619 | 0.89 | POLB (0.61) | TOP2ATOP2BKDM1APOLBRAD52 | |
| SCHEMBL7567719 | 0.89 | TOP2A (0.73) | TOP2ATOP2BKDM1APOLBRAD52 | |
| SCHEMBL7564523 | 0.81 | TOP2A (0.71) | TOP2ATOP2BKDM1APOLBRAD52 | |
| SCHEMBL8490361 | 0.78 | TOP2A (0.80) | TOP2ATOP2BKDM1APOLBRAD52 | |
| SCHEMBL7562964 | 0.77 | TOP2A (0.71) | TOP2ATOP2BPOLBRAD52KMT2A | |
| SCHEMBL7563689 | 0.77 | TOP2A (0.77) | TOP2ATOP2BKDM1APOLBRAD52 | |
| SCHEMBL8489520 | 0.77 | TOP2A (1.00) | TOP2ATOP2BKDM1APOLBRAD52 | |
| SCHEMBL3981533 | 0.77 | TOP2A (0.80) | TOP2ATOP2BKDM1APOLBRAD52 | |
| SCHEMBL3985960 | 0.77 | TOP2A (0.59) | TOP2ATOP2BKDM1APOLBRAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020111491-A1 | 9-aminoacridine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111491-A1 | 9-aminoacridine derivatives and process for the preparation thereof | ALKBH1, ADCY9, CCR9 | TOP2A 1105/4885TOP2B 841/4885KDM1A 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.